Skip to content

foryourhealth111-pixel/Vibe-Skills / bundled/skills/clinical-reports

clinical-reports

Verified

Write comprehensive clinical reports including case reports (CARE guidelines), diagnostic reports (radiology/pathology/lab), clinical trial reports (ICH-E3, SAE, CSR), and patient documentation (SOAP, H&P, discharge summaries). Full support with templates, regulatory compliance (HIPAA, FDA, ICH-GCP), and validation tools.

assets/clinical_trial_csr_template.md

View on GitHub
# Clinical Study Report (CSR) Template
## ICH-E3 Format

---

# TITLE PAGE

**Study Title:** [Full descriptive title including compound, indication, phase]

**Protocol Number:** [Sponsor protocol number]  
**Protocol Version:** [Final protocol version and date]

**Sponsor:** [Company name and address]  
**Compound/Drug Name:** [Generic and proprietary names, compound code]  
**Indication:** [Therapeutic area and specific indication studied]

**Study Phase:** [I / II / III / IV]  
**Study Type:** [Interventional / Observational]

**Report Date:** [MM/DD/YYYY]  
**Report Version:** [Version number]

**Medical Expert:** [Name, MD, Title]  
**Biostatistician:** [Name, PhD, Title]

**Confidentiality Statement:**
"This document contains confidential information belonging to [Sponsor]. It may not be reproduced or distributed without permission."

---

# SYNOPSIS

**Title:** [Abbreviated title]

**Protocol Number:** [Number]  
**Study Phase:** [Phase]  
**Study Period:** [Start date - End date]

## Study Objectives

**Primary Objective:**
[State primary objective clearly and concisely]

**Secondary Objectives:**
- [Secondary objective 1]
- [Secondary objective 2]

## Methodology

**Study Design:**
[Randomized, double-blind, placebo-controlled, parallel-group, etc.]

**Study Population:**
- Target population: [Patient population]
- Key inclusion criteria: [Main criteria]
- Key exclusion criteria: [Main criteria]

**Sample Size:**
- Planned: [N participants]
- Randomized: [N participants]
- Completed: [N participants]

**Treatment:**
- Treatment A: [Drug name, dose, route, frequency]
- Treatment B: [Comparator/placebo]
- Treatment duration: [Weeks/months]
- Follow-up duration: [Weeks/months]

**Endpoints:**

Primary:
- [Primary endpoint definition and timepoint]

Secondary:
- [Secondary endpoint 1]
- [Secondary endpoint 2]

**Statistical Methods:**
[Brief description of analysis approach, significance level, handling of multiplicity]

## Results

**Participant Disposition:**
- Screened: [N]
- Randomized: [N Treatment A, N Treatment B]
- Completed: [N Treatment A, N Treatment B]
- Discontinued: [N overall, % - main reasons]

**Demographics and Baseline:**
[Summary of key baseline characteristics, comparability across groups]

**Efficacy Results:**

Primary Endpoint:
- [Result for Treatment A vs B, effect size, 95% CI, p-value]

Secondary Endpoints:
- [Results for each secondary endpoint]

**Safety Results:**
- Any AE: [% Treatment A vs B]
- Treatment-related AE: [% Treatment A vs B]
- Serious AE: [% Treatment A vs B]
- Discontinuations due to AE: [% Treatment A vs B]
- Deaths: [N Treatment A vs B]
- Common AEs (≥5%): [List with percentages]

## Conclusions

[Overall conclusions regarding efficacy and safety, benefit-risk assessment]

---

# TABLE OF CONTENTS

[Detailed table of contents with page numbers]

---

# LIST OF ABBREVIATIONS

| Abbreviation | Definition |
|--------------|------------|
| AE | Adverse Event |
| ANCOVA | Analysis of Covariance |
| CI | Confidence Interval |
| CSR | Clinical Study Report |
| FAS | Full Analysis Set |
| GCP | Good Clinical Practice |
| ICF | Informed Consent Form |
| ITT | Intent-to-Treat |
| PP | Per-Protocol |
| SAE | Serious Adverse Event |
| SD | Standard Deviation |
| [Add study-specific abbreviations] | |

---

# ETHICS (Section 2)

## 2.1 Independent Ethics Committee (IEC) or Institutional Review Board (IRB)

[List of all IECs/IRBs that approved the study]

| Site Number | Institution | IRB/IEC Name | Approval Date |
|-------------|------------|--------------|---------------|
| 001 | [Institution] | [IRB name] | [MM/DD/YYYY] |

## 2.2 Ethical Conduct of the Study

This study was conducted in accordance with:
- ICH Good Clinical Practice (GCP) E6(R2)
- Declaration of Helsinki (current version)
- Applicable regulatory requirements
- Sponsor Standard Operating Procedures

## 2.3 Patient Information and Consent

Informed consent was obtained from all participants before any study-specific procedures. The informed consent process included:
- Written information about study purpose, procedures, risks, and benefits
- Opportunity to ask questions
- Voluntary participation with right to withdraw
- Signatures of participant and person obtaining consent
- Copy provided to participant

---

# INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE (Section 3)

## 3.1 Investigators and Study Centers

[Table listing all investigators, sites, and enrollment]

| Site No. | Investigator | Institution | City, Country | Subjects Enrolled |
|----------|--------------|-------------|---------------|-------------------|
| 001 | [Name, MD] | [Institution] | [City, Country] | [N] |

**Coordinating Investigator:** [Name, if applicable]

## 3.2 Study Administrative Structure

**Sponsor:**
- Medical Monitor: [Name, credentials]
- Project Manager: [Name]
- Biostatistician: [Name, credentials]

**Contract Research Organization (CRO):** [Name, if applicable]
- [Responsibilities]

## 3.3 Responsibilities of Parties Involved

[Description of sponsor, investigator, CRO, DSMB responsibilities]

---

# INTRODUCTION (Section 4)

## 4.1 Background

[Detailed background on disease/condition, unmet medical need, treatment landscape]

## 4.2 Nonclinical Studies

[Summary of relevant preclinical pharmacology, toxicology, and safety findings]

## 4.3 Previous Clinical Studies

[Summary of prior clinical experience with investigational product]

## 4.4 Study Rationale and Objectives

[Justification for conducting this study, specific objectives]

---

# STUDY OBJECTIVES AND PLAN (Section 5)

## 5.1 Objectives and Endpoints

**Primary Objective:**
[Objective statement]

**Primary Endpoint:**
[Detailed endpoint definition, measurement method, timepoint]

**Secondary Objectives:**
1. [Objective]
2. [Objective]

**Secondary Endpoints:**
1. [Endpoint definition]
2. [Endpoint definition]

## 5.2 Study Design

[Detailed description of study design with diagram if helpful]

**Design Type:** [Parallel, crossover, factorial, etc.]
**Blinding:** [Double-blind, open-label, etc.]
**Randomization:** [1:1, 2:1, stratified, etc.]
**Duration:** [Treatment period, follow-up period]

**Study Schema:**
[Flow diagram showing screening, randomization, treatment periods, follow-up]

## 5.3 Study Population

**Key Inclusion Criteria:**
1. [Criterion]
2. [Criterion]

**Key Exclusion Criteria:**
1. [Criterion]
2. [Criterion]

## 5.4 Treatments

**Investigational Product:**
- Name: [Generic, trade, code]
- Formulation: [Tablet, capsule, injection]
- Dose: [Dose and regimen]
- Route: [PO, IV, SC, etc.]
- Packaging and labeling: [Description]

**Comparator:**
[Similar details for comparator or placebo]

**Concomitant Medications:**
[Permitted and prohibited medications]

## 5.5 Sample Size Determination

**Target Sample Size:** [N per group, N total]

**Justification:**
- Assumed effect size: [Value]
- Variability (SD): [Value]
- Type I error (α): [0.05]
- Power (1-β): [80% or 90%]
- Expected dropout rate: [%]
- Two-sided test

## 5.6 Statistical Analysis Plan

**Analysis Populations:**
- Full Analysis Set (FAS): [Definition]
- Per-Protocol Set (PPS): [Definition]
- Safety Analysis Set: [Definition]

**Statistical Methods:**
- Primary endpoint: [Method - e.g., ANCOVA with baseline as covariate]
- Secondary endpoints: [Methods]
- Handling of missing data: [Approach]
- Multiplicity adjustment: [Method if applicable]
- Interim analyses: [If planned]

**Significance Level:** α = 0.05 (two-sided)

---

# STUDY PATIENTS (Section 6)

## 6.1 Disposition of Patients

**Participant Flow (CONSORT Diagram):**

[Include detailed CONSORT diagram showing screening through analysis]

**Summary Table:**

| Category | Treatment A | Treatment B | Total |
|----------|-------------|-------------|-------|
| Screened | N | N | N |
| Screen failures | N (%) | N (%) | N (%) |
| Randomized | N | N | N |
| Received treatment | N (%) | N (%) | N (%) |
| Completed | N (%) | N (%) | N (%) |
| Discontinued | N (%) | N (%) | N (%) |
| - Adverse event | N (%) | N (%) | N (%) |
| - Lack of efficacy | N (%) | N (%) | N (%) |
| - Lost to follow-up | N (%) | N (%) | N (%) |
| - Withdrawal of consent | N (%) | N (%) | N (%) |
| - Other | N (%) | N (%) | N (%) |

## 6.2 Protocol Deviations

**Major Protocol Deviations:**
[Summary of major deviations, impact on data, subjects affected]

**Important Protocol Deviations by Category:**

| Deviation Type | Treatment A | Treatment B | Total |
|----------------|-------------|-------------|-------|
| Inclusion/exclusion criteria | N (%) | N (%) | N (%) |
| Dosing errors | N (%) | N (%) | N (%) |
| Prohibited medications | N (%) | N (%) | N (%) |
| Missed visits | N (%) | N (%) | N (%) |

---

(Continues with sections 7-14 following ICH-E3 structure...)

---

**Note:** This is an abbreviated template. A complete CSR following ICH-E3 is typically 50-300 pages with extensive appendices. Key sections to complete:
- Section 7: Efficacy Evaluation
- Section 8: Safety Evaluation
- Section 9: Discussion and Overall Conclusions
- Section 10: Tables, Figures, and Graphs
- Section 11: References
- Section 12-14: Appendices (Protocol, CRFs, Investigator list, etc.)


writing-skillsobra/superpowersUse when creating new skills, editing existing skills, or verifying skills work before deploymentStars: 323kUpdated Claude CodeCodexVerifiedInstall
xlsxanthropics/skillsUse this skill any time a spreadsheet file is the primary input or output. This means any task where the user wants to: open, read, edit, or fix an existing .xlsx, .xlsm, .xltx, .csv, or .tsv file (e.g., adding columns, computing formulas, formatting, charting, cleaning messy data); create a new spreadsheet from scratch or from other data sources; or convert between tabular file formats. Trigger especially when the user references a spreadsheet file by name or path — even casually (like "the xlsx in my downloads") — and wants something done to it or produced from it. Also trigger for cleaning or restructuring messy tabular data files (malformed rows, misplaced headers, junk data) into proper spreadsheets. The deliverable must be a spreadsheet file. Do NOT trigger when the primary deliverable is a Word document, HTML report, standalone Python script, database pipeline, or Google Sheets API integration, even if tabular data is involved.Stars: 198kUpdated Claude CodeCodexVerifiedInstall
shipping-and-launchaddyosmani/agent-skillsPrepares production launches. Use when preparing to deploy to production, or when asking what needs to be in place before shipping. Use when you need a pre-launch checklist, when setting up monitoring, when planning a staged rollout, or when you need a rollback strategy.Stars: 119kUpdated Claude CodeCodexVerifiedInstall
childhoodthedotmack/claude-memBabysit a shipped release after merge, publication, or deployment. Verify published packages, production behavior, installed plugins, and late CI or user reports until the observation window is clean; use babysit for PR readiness before release.Stars: 118kUpdated Claude CodeCodexVerifiedInstall